Beyond PI3Ks: targeting phosphoinositide kinases in disease.

Burke, John E; Triscott, Joanna; Emerling, Brooke M; Hammond, Gerald R V (2023). Beyond PI3Ks: targeting phosphoinositide kinases in disease. Nature reviews. Drug discovery, 22(5), pp. 357-386. Nature Publ. Group 10.1038/s41573-022-00582-5

Text s41573-022-00582-5.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (6MB) | Request a copy

Lipid phosphoinositides are master regulators of almost all aspects of a cell's life and death and are generated by the tightly regulated activity of phosphoinositide kinases. Although extensive efforts have focused on drugging class I phosphoinositide 3-kinases (PI3Ks), recent years have revealed opportunities for targeting almost all phosphoinositide kinases in human diseases, including cancer, immunodeficiencies, viral infection and neurodegenerative disease. This has led to widespread efforts in the clinical development of potent and selective inhibitors of phosphoinositide kinases. This Review summarizes our current understanding of the molecular basis for the involvement of phosphoinositide kinases in disease and assesses the preclinical and clinical development of phosphoinositide kinase inhibitors.

Interest & Impact

Downloads

1 since deposited on 16 Nov 2022
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item